Cargando…

PD-1 and ICOS coexpression identifies tumor-reactive CD4(+) T cells in human solid tumors

CD4(+) Th cells play a key role in orchestrating immune responses, but the identity of the CD4(+) Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset...

Descripción completa

Detalles Bibliográficos
Autores principales: Duhen, Rebekka, Fesneau, Olivier, Samson, Kimberly A., Frye, Alexandra K., Beymer, Michael, Rajamanickam, Venkatesh, Ross, David, Tran, Eric, Bernard, Brady, Weinberg, Andrew D., Duhen, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197519/
https://www.ncbi.nlm.nih.gov/pubmed/35439168
http://dx.doi.org/10.1172/JCI156821
Descripción
Sumario:CD4(+) Th cells play a key role in orchestrating immune responses, but the identity of the CD4(+) Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4(+) Th cells distinct from FOXP3(+) Tregs that coexpressed programmed cell death 1 (PD-1) and ICOS. These tumor-infiltrating lymphocyte CD4(+) Th cells (CD4(+) Th TILs) had a tissue-resident memory phenotype, were present in MHC class II–rich areas, and proliferated in the tumor, suggesting local antigen recognition. The T cell receptor repertoire of the PD-1(+)ICOS(+) CD4(+) Th TILs was oligoclonal, with T cell clones expanded in the tumor, but present at low frequencies in the periphery. Finally, these PD-1(+)ICOS(+) CD4(+) Th TILs were shown to recognize both tumor-associated antigens and tumor-specific neoantigens. Our findings provide an approach for isolating tumor-reactive CD4(+) Th TILs directly ex vivo that will help define their role in the antitumor immune response and potentially improve future adoptive T cell therapy approaches.